We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improve the Treatment of Thoracic Esophageal Cancer

This study is currently recruiting participants.
Verified May 2017 by Peng Lin, Sun Yat-sen University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01137123
First Posted: June 4, 2010
Last Update Posted: May 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Peng Lin, Sun Yat-sen University
  Purpose

The purpose of this study is

  1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on the staging and prognosis of resectable esophageal cancer, which defined by the International Association of esophageal disease(ISDE) - standard mediastinal lymphadenectomy,total mediastinal lymphadenectomy and three field lymphadenectomy,and to find out reasonable range of lymphadenectomy.
  2. To compare the effects of Chemotherapy Group (Docetaxel + Nedaplatin) with Control Group on the prognosis of resectable thoracic esophageal cancer,and to explore the indications of adjuvant chemotherapy.

Condition Intervention Phase
Thoracic Esophageal Squamous Cell Carcinoma Drug: adjuvant chemotherapy Procedure: standard two field Lymphadenectomy Procedure: Total two field Lymphadenectomy Procedure: three field Lymphadenectomy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer

Resource links provided by NLM:


Further study details as provided by Peng Lin, Sun Yat-sen University:

Primary Outcome Measures:
  • survival rate [ Time Frame: 5 years ]
    1. Disease-free survival
    2. overall survival


Estimated Enrollment: 122
Study Start Date: April 2010
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: standard two field +follow-up Procedure: standard two field Lymphadenectomy
Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Other Name: two field(S)
Experimental: standard two field +adjuvant chemotherapy Drug: adjuvant chemotherapy
Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Procedure: standard two field Lymphadenectomy
Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Other Name: two field(S)
Experimental: total two field+follow-up Procedure: Total two field Lymphadenectomy
Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Other Name: two field(T)
Experimental: total two field+adjuvant chemotherapy Drug: adjuvant chemotherapy
Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Procedure: Total two field Lymphadenectomy
Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Other Name: two field(T)
Experimental: three field+follow-up Procedure: three field Lymphadenectomy
Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
Other Name: three field
Experimental: three field+adjuvant chemotherapy Drug: adjuvant chemotherapy
Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Procedure: three field Lymphadenectomy
Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
Other Name: three field

Detailed Description:

According to different location of the primary lesion,the subject can be allocated to two sub-groups:

The patient with upper or middle thoracic esophageal cancer may be assigned to two field(T)-total mediastinal lymphadenectomy group,which is control group in this study or three field lymphadenectomy-Abdominal + mediastinal + cervical lymphadenectomy group,which is study group in this study randomly.

After the operation,the patient whose primary lesion is completely(R0) resected will be assigned to adjuvant chemotherapy group or interview group randomly.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age≤70 years old;
  2. Karnofsky Performance Status(KPS)≥80;
  3. Pathological diagnosis is squamous cell carcinoma of thoracic esophageal which is treated initially;
  4. Clinical stage is c T 1 ~ 3 N 0 ~ 1 according to the results of endoscopic ultrasonography,chest and abdomen CT and neck ultrasonic.
  5. The preoperative evaluation of organ function is tolerant of surgery and chemotherapy;
  6. The subject can understand and sign the informed consent form (ICF);
  7. The following laboratory tests, made in 4 weeks before first medication, confirmed that bone marrow, liver and kidney function in line with the requirements to participate in research; Hemoglobin(HGB)≥9.0g/L; absolute neutrophils count(ANC)≥1.5×109/L; platelet count(PLT)≥100×109/L; total bilirubin(TBIL)≤1.5N;aspartate aminotransferase (AST)≤2.5N;alanine aminotransferase(ALT)≤2.5N;prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range;endogenous creatinine clearance rate(CRE)≤1.5N.

Exclusion Criteria:

  1. Cervical esophageal cancer and Non-squamous cell carcinoma of thoracic esophageal cancer;
  2. Advanced Esophageal Cancer;
  3. Prior malignancy in 5 years recently;
  4. History of previous chest radiotherapy;
  5. History of cardio-cerebral vascular accident in 6 months lately;
  6. The subject can not understand and sign the informed consent form(ICF).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01137123


Contacts
Contact: Peng Ling, professor +86-20-87343314 linpeng@sysucc.org.cn
Contact: Tan Zi Hui +86-20-87343736 tanzh@sysucc.org.cn

Locations
China, Guangdong
Sun Yat-sen Uniersity Cancer Center Recruiting
GuangZhou, Guangdong, China, 510060
Contact: Peng Lin, Professor    +86-20-87343314    linpeng@sysucc.org.cn   
Contact: Jun Zeng    +86-20-87343736    xingrp@sysucc.org.cn   
Principal Investigator: Peng Lin, Professor         
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Principal Investigator: Peng Lin, Professor 651, Dongfeng Road East, Guangzhou, P. R. China
  More Information

Additional Information:
Publications:

Responsible Party: Peng Lin, Sun Yat-sen University Cancer Center, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT01137123     History of Changes
Other Study ID Numbers: 2007044
First Submitted: June 3, 2010
First Posted: June 4, 2010
Last Update Posted: May 15, 2017
Last Verified: May 2017

Keywords provided by Peng Lin, Sun Yat-sen University:
esophageal squamous cell carcinoma

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Esophageal Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases